Recent studies have shown that amplified MET is a clinically valid therapeutic target for MET inhibitors or MET-tyrosine kinase inhibitors (e.g. crizotinib) approved recently for the treatment of patients with NSCLC [9]. The gene discussed is MET; the disease is non-small cell lung carcinoma.